---
title: 'Senior Director, Drug Safety and Pharmacovigilance at Annexon Biosciences'
canonical: 'https://feeny.ai/job/senior-director-drug-safety-and-pharmacovigilance-annexon-biosciences-san-w7jhxhsm0t09'
type: 'job'
last_seen: '2026-09-13'
---

# Senior Director, Drug Safety and Pharmacovigilance at Annexon Biosciences

- **Company:** Annexon Biosciences
- **Location:** San Francisco, CA
- **Posted:** 2026-05-21
- **Last confirmed live:** 2026-09-13
- **Apply:** https://job-boards.greenhouse.io/annexonbioscience/jobs/4698637005

## Job description

Company:

At Annexon Biosciences we are a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Our novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, we are rigorously advancing our mid-to late-stage clinical trials to bring new potential treatments to patients as quickly as possible. At Annexon, you’ll be part of a team committed to making an impact together.

For more information on Annexon and our pipeline, check out our site [Annexon Biosciences](https://annexonbio.com/) & [Annexon Pipeline](https://annexonbio.com/pipeline/). We trade on Nasdaq under the ticker symbol ANNX and are headquartered in Brisbane, CA.

We're seeking exceptional talent from all backgrounds to fuel our growth. At Annexon, we're building a diverse, equitable, and inclusive workplace. We value unique perspectives and unconventional paths. If you're the best candidate for the job, even if you don't perfectly fit the traditional mold, we encourage you to apply. Learn more about our commitment to diversity, equity, inclusion, and our company [culture](https://annexonbio.com/our-culture/)!

Position:

The Senior Director, Drug Safety and Pharmacovigilance will work closely with the relevant Medical Monitors and Clinical Development Lead Physician(s) to facilitate signal detection monitoring, product risk-benefit assessment, and safety assessment activities of investigational products within individual clinical programs and – as applicable – across the portfolio. This individual will be responsible for strategic leadership and medical oversight of assigned Annexon product(s) and will report to the VP of Drug Safety and Pharmacovigilance.

Responsibilities include:

- Reviews all appropriate safety data from various sources throughout the product development lifecycle.
- Facilitates medical assessment of all safety related data (AEs, SAE, SUSAR, AESI etc.) for assigned product(s).
- Ensures accuracy of case narratives, coding and medical reviews and ensures appropriate queries are raised for a comprehensive medical review by relevant company physician(s).
- Authors/reviews relevant sections of aggregate safety reports and ensures the overall quality of documents.
- Authors, reviews and provides input as applicable for drug-safety related regulatory reports and clinical study documents including Clinical Study Protocols, Informed Consent Forms, Investigator’s Brochures, Integrated Summary of Safety (ISS), MedDRA coding of AEs, product package labeling, Company Core Safety Information (CCSI)
- Responsible for drafting responses to queries from regulatory authorities or health care professionals on safety issues and any legal queries and requests involving safety issues.
- Lead the analysis, identification and reporting or possible trends and concerns regarding compounds and key related products, including the identification and evaluation of safety signals through the assessment of single case reports, aggregate safety reports and review of relevant literature for safety information pertinent to product safety.
- Participate in the preparation and provision of PV training as needed.
- Insert bulleted list of core responsibilities [this is not an exhaustive list of tasks]
- Include any central relationships/collaborations
- Various other tasks as necessary for the position based on manager’s discretion
- Contribute to and participate in the development and maintenance of a positive team-focused company culture
- Represent Drug Safety and Pharmacovigilance on DSMBs
- Participates in inspection readiness activities and preparation as needed.

Education, Experience, and Skills:

Required:

- Advanced degree in Medicine (e.g., MD, DO) with a minimum of 8-10 years of experience in a Drug Safety and Pharmacovigilance role in a biopharma company.
- A combination of education and experience that may be deemed appropriate for the position as per the hiring manager and the human resources team’s discretion
- A thorough understanding of the global pharmacovigilance regulatory environment with working knowledge of US and EU regulations (e.g. MedDRA, WHODRL), ICH guidelines, and a working understanding of drug safety databases (e.g. ARGUS), effective project management skills, a demonstrated ability to provide critical and timely insight, and analytical problem-solving skills with a broad perspective
- Flexibility and agility to function on various levels of the role as required in a fast-growing environment.
- Demonstrated competence in obtaining, analyzing, disseminating and reporting safety information in compliance with global regulations.

Preferred:

- Experience filing submissions for marketing authorization
- Medical knowledge with the ability to interpret, synthesize, and communicate complex safety data.

Salary Range: $300,000 - $375,000

Location: Annexon Biosciences is located in Brisbane, California This role operates under a hybrid work arrangement and requires regular onsite collaboration at our office. Candidates should be located within commuting distance and able to work in the office multiple days each week.

Benefits:

- A stimulating and rewarding workplace includes flexible work schedules, remote opportunities and the ability to achieve a work-life balance.
- Shuttle service from BART, CalTrain and the Ferry.
- Annexon offers a competitive base salary and equity participation, employee stock purchase plan, as well as a comprehensive health benefit package that includes medical, dental, vision, 401(k), flexible spending plans, and other benefits.

Annexon Biosciences is an Equal Opportunity Employer, and we prohibit discrimination or harassment of any kind.  We are committed to fostering an environment where ALL people are welcome and supported. We cultivate a culture of inclusion for all employees that respects their individual strengths, views, and experiences. We believe that our differences enable us to be a better team – one that makes better decisions, drives innovation, and delivers better business results. Creativity and innovation flourish in an environment of openness, inclusion, and mutual respect.

## About Annexon Biosciences

## Company Overview
- **One-liner**: Annexon Biosciences is a clinical-stage biopharmaceutical company pioneering the development of C1q inhibitors to stop classical complement-mediated neuroinflammation in autoimmune, neurodegenerative, and ophthalmic diseases.
- **Entity Type**: Public (Nasdaq: ANNX)
- **Headquarters**: Brisbane, California, USA
- **Founded**: 2007
- **Founders**: Dr. Ben Barres (co‑founder, deceased) and Dr. Arnon Rosenthal

## Core Business
- **Industry**: Biopharmaceuticals – complement‑targeted therapeutics
- **Target Customers**: Patients and healthcare providers treating classical complement‑mediated diseases (body, brain, eye); B2B partnerships with clinical sites and payers
- **Mission**: “Deliver game‑changing therapies to patients so that they can live their best lives” [annexonbio.com](https://annexonbio.com/about/)

## Products & Services
Annexon’s pipeline is based on inhibiting C1q, the initiating molecule of the classical complement pathway. Key investigational candidates:
- **ANX005**: A monoclonal antibody targeting C1q for intravenous administration. Lead indication is Guillain‑Barré Syndrome (GBS); completed enrollment in a Phase 3 pivotal program – the first such program in GBS in 40 years – and has Orphan Drug Designation from the EMA [annexonbio.com](https://annexonbio.com/about/)
- **ANX007**: An intravitreal antibody fragment targeting C1q for ophthalmic use. Demonstrated statistically significant, dose‑dependent preservation of visual function in a Phase 2 trial in geographic atrophy (GA) [annexonbio.com](https://annexonbio.com/about/)
- **ANX009**: A subcutaneous formulation of ANX005 designed for chronic autoimmune and neurodegenerative indications. Achieved full target engagement in the blood compartment in a Phase 1 healthy volunteer study [annexonbio.com](https://annexonbio.com/about/)
- **ANX1502**: An oral small‑molecule inhibitor of the classical complement pathway. Achieved target pharmacokinetics in a Phase 1 healthy volunteer study [annexonbio.com](https://annexonbio.com/about/)

## Market Standing
- **Valuation / Market Cap**: Not publicly available from provided sources (public company, market cap fluctuates)
- **Key Metric**: Publicly traded (Nasdaq: ANNX); recent major milestones include Phase 3 completion for ANX005 in GBS and Phase 2 data for ANX007 in GA
- **Notable Investors / Partners**: Leaders on board and scientific advisory board include Stephen Hauser (MD, UCSF), Beth Stevens (PhD, Harvard), David Holtzman (MD, Washington University), and others. The co‑founder Dr. Ben Barres was a highly respected neuroscientist [annexonbio.com](https://annexonbio.com/about/)
- **Growth Signals**: Initial public offering in 2020 funded pipeline expansion; active recruiting for senior clinical and medical affairs roles (Senior Director, Clinical Development; VP, Drug Safety; etc.) suggests advancement toward late‑stage trials and potential commercialization [greenhouse.io](https://job-boards.greenhouse.io/annexonbioscience)

## Competitive Advantages
- **First‑in‑class C1q inhibitor focus**: By targeting the top of the classical complement pathway, Annexon aims to block all downstream damaging components rather than a single downstream effector.
- **Broad pipeline across three therapeutic areas** (autoimmunity, neurodegeneration, ophthalmology) targeting nearly 10 million patients worldwide.
- **Biomarker‑driven, disciplined strategy** to improve probability of technical success and deliver precision medicine [ir.annexonbio.com](https://ir.annexonbio.com/corporate-profile)
- **Strong scientific foundation** built on decades of research by co‑founder Dr. Ben Barres on C1q’s role in synapse loss.

## Strategic Focus
- Completing the first Phase 3 program for GBS in 40 years (ANX005) and preparing for regulatory submissions.
- Advancing ANX007 through pivotal trials for geographic atrophy and exploring glaucoma.
- Developing subcutaneous and oral formulations (ANX009, ANX1502) to expand into chronic, less invasive treatment paradigms.
- Employing precision‑medicine biomarkers to identify patients most likely to benefit from classical complement inhibition.

## Why Work Here
- **Culture**: Described as “show up with your heart and mind … team‑based, follow the science.” Core values include warrior spirit, all‑for‑one teamwork, sound judgment, passion, and a thrive mentality [annexonbio.com/careers](https://annexonbio.com/careers/)
- **Work Environment**: Flexible work schedules, remote opportunities, and a Brisbane, CA office with shuttle service from BART, CalTrain, and the Ferry [annexonbio.com/careers](https://annexonbio.com/careers/)
- **Benefits**: Competitive base salary, equity participation, employee stock purchase plan (ESPP), medical/dental/vision insurance, 401(k), flexible spending plans, and a focus on work‑life balance [annexonbio.com/careers](https://annexonbio.com/careers/)
- **Team**: About 4 open positions as of mid‑2026 (Senior Director Clinical Development, VP Drug Safety, etc.) – a small, driven team where contributions are visible and valued [greenhouse.io](https://job-boards.greenhouse.io/annexonbioscience)

## Sources
1. [annexonbio.com – Home](https://annexonbio.com/)
2. [ir.annexonbio.com – Corporate Profile](https://ir.annexonbio.com/corporate-profile)
3. [annexonbio.com – About (Leadership, History, Mission)](https://annexonbio.com/about/)
4. [annexonbio.com – Careers (Culture, Benefits, Values)](https://annexonbio.com/careers/)
5. [greenhouse.io – Jobs at Annexon Biosciences](https://job-boards.greenhouse.io/annexonbioscience)

## Other roles at Annexon Biosciences

- [Senior Director, Global Scientific Communications](https://feeny.ai/job/senior-director-global-scientific-communications-annexon-biosciences-san-ygq0cdyxzd03) — San Francisco, CA
- [Executive Director & Head Clinical Data Management](https://feeny.ai/job/executive-director-head-clinical-data-management-annexon-biosciences-san-srwq0ehec0wz) — San Francisco, CA
- [Field Medical Director (MSL) – Ophthalmology (Southeast Region)](https://feeny.ai/job/field-medical-director-msl-ophthalmology-southeast-region-annexon-biosciences-f7eyw4qqefam) — San Francisco, CA
- [Senior Director, Regulatory Affairs](https://feeny.ai/job/senior-director-regulatory-affairs-annexon-biosciences-san-francisco-b2av8f6dqd9f) — San Francisco, CA
- [Senior Director, Medical Writing](https://feeny.ai/job/senior-director-medical-writing-annexon-biosciences-san-francisco-kxv9t4ghnxry) — San Francisco, CA
- [Associate Director, Clinical Trial Management](https://feeny.ai/job/associate-director-clinical-trial-management-annexon-biosciences-san-francisco-h3rh38k6a3ek) — San Francisco, CA
- [Vice President, Medical Affairs-Neuroscience](https://feeny.ai/job/vice-president-medical-affairs-neuroscience-annexon-biosciences-san-francisco-vec8c090165d) — San Francisco, CA
- [Vice President, Clinical Development-Ophthalmology](https://feeny.ai/job/vice-president-clinical-development-ophthalmology-annexon-biosciences-san-8j8gnj3vpggn) — San Francisco, CA
- [Vice President, Medical Affairs-Ophthalmology](https://feeny.ai/job/vice-president-medical-affairs-ophthalmology-annexon-biosciences-san-francisco-4k8s7zf170d6) — San Francisco, CA